scholarly journals Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making

2016 ◽  
Vol 115 (9) ◽  
pp. 1039-1047 ◽  
Author(s):  
Yong-Fa Zhang ◽  
Jie Zhou ◽  
Wei Wei ◽  
Ru-Hai Zou ◽  
Min-Shan Chen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Decision Making ◽  
Hepatic Resection ◽  
Intermediate Stage

scholarly journals Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients

2019 ◽  
Vol 51 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Zhang Zhaohui ◽  
Shen Shunli ◽  
Chen Bin ◽  
Li Shaoqiang ◽  
Hua Yunpeng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Survival Benefit ◽  
Intermediate Stage

scholarly journals Comparison of prognosis after hepatic resection of hepatocellular carcinoma between intermediate stage tumor and early stage tumor

2018 ◽  
Vol 29 ◽  
pp. v92-v93
Author(s):  
J. Arita ◽  
T. Kokudo ◽  
N. Akamatsu ◽  
J. Kaneko ◽  
T. Ishizawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Early Stage ◽  
Intermediate Stage ◽  
Early Stage Tumor

scholarly journals Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: A multicenter study from Japan

2017 ◽  
Vol 108 (7) ◽  
pp. 1414-1420 ◽  
Author(s):  
Toshifumi Tada ◽  
Takashi Kumada ◽  
Hidenori Toyoda ◽  
Kunihiko Tsuji ◽  
Atsushi Hiraoka ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Multicenter Study ◽  
Intermediate Stage

Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma

Surgery ◽  
2016 ◽  
Vol 160 (5) ◽  
pp. 1227-1235 ◽  
Author(s):  
Hiroshi Wada ◽  
Hidetoshi Eguchi ◽  
Takehiro Noda ◽  
Hisataka Ogawa ◽  
Daisaku Yamada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Selection Criteria ◽  
Intermediate Stage ◽  
Multiple Hepatocellular Carcinoma

Hepatic resection is superior to transarterial chemoembolization for treating intermediate-stage hepatocellular carcinoma

2016 ◽  
Vol 37 (7) ◽  
pp. 1083-1084 ◽  
Author(s):  
Jian-Hong Zhong ◽  
Ning-Fu Peng ◽  
Xue-Mei You ◽  
Liang Ma ◽  
Le-Qun Li
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Transarterial Chemoembolization ◽  
Intermediate Stage

Sorafenib versus transarterial chemoembolization as adjuvant therapies for patients with hepatocellular carcinoma and microvascular invasion.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 244-244 ◽  
Author(s):  
Xinyu Bi ◽  
Jie Gao ◽  
Jianqiang Cai
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatic Resection ◽  
Transarterial Chemoembolization ◽  
Standard Of Care ◽  
Intermediate Stage ◽  
Microvascular Invasion ◽  
Rank Test ◽  
Control Group ◽  
Adjuvant Therapies ◽  
Sorafenib Group

244 Background: Microvascular invasion (MVI) is a risk factor for poor prognosis following curative resection in hepatocellular carcinoma (HCC). Currently, there is no standard of care for patients with HCC and MVI. The present study compared the effectiveness of sorafenib and transarterial chemoembolization (TACE) as adjuvant therapies following hepatic resection in patients with early and intermediate-stage HCC and MVI. Methods: This bi-center retrospective study examined 70 patients with HCC and MVI treated by hepatic resection between June 2009 and March 2018. Twenty-four patients received no postoperative adjuvant therapy (control), 19 received TACE and 27 received sorafenib. Recurrence-free survival (RFS) and overall survival (OS) were compared by the log-rank test. Results: Subjects consisted of 62 males and 8 females, with a median age of 53.5 (range, 28-82) years. The median follow-up was 26.0 (range, 4.1-103.1) months. RFS in the sorafenib group was significantly improved compared with the TACE group (P=0.048), but not with the control group. OS in the sorafenib group was significantly improved compared with both TACE (P=0.015; 2-year OS: 100% vs. 78.6%) and control (P=0.023; 2-year OS: 100% vs. 80.0%) groups. Conclusions: Adjuvant sorafenib following hepatic resection improved OS in patients with HCC and MVI and might be a better choice than adjuvant TACE.

Sign in / Sign up

Export Citation Format

Share Document